scholarly journals Estimating region-specific fuel economy in the United States from real-world driving cycles

2020 ◽  
Vol 86 ◽  
pp. 102448 ◽  
Author(s):  
Brennan Borlaug ◽  
Jacob Holden ◽  
Eric Wood ◽  
Byungho Lee ◽  
Justin Fink ◽  
...  
Keyword(s):  
United States ◽  
Fuel Economy ◽  
Real World ◽  
The United States ◽  
Driving Cycles

scholarly journals Real-World Fetal Exposure to Acne Treatments in the United States: A Retrospective Analysis from 2006 to 2015

Drug Safety ◽  
2021 ◽  
Vol 44 (4) ◽  
pp. 447-454 ◽  
Author(s):  
Yasser Albogami ◽  
Amir Sarayani ◽  
Juan M. Hincapie-Castillo ◽  
Almut G. Winterstein
Keyword(s):  
United States ◽  
Retrospective Analysis ◽  
Real World ◽  
The United States ◽  
Fetal Exposure

scholarly journals P-21 Real-world outcomes in patients with advanced or metastatic gastric adenocarcinoma in the United States

2021 ◽  
Vol 32 ◽  
pp. S103
Author(s):  
D. Beachler ◽  
F. Lamy ◽  
F. Kolitsopoulos ◽  
J. Dinh ◽  
A. Papazian ◽  
...  
Keyword(s):  
United States ◽  
Gastric Adenocarcinoma ◽  
Real World ◽  
The United States

scholarly journals Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study

BMC Cancer ◽  
2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Daniel C. Beachler ◽  
Cynthia de Luise ◽  
Aziza Jamal-Allial ◽  
Ruihua Yin ◽  
Devon H. Taylor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
United States ◽  
Pulmonary Embolism ◽  
Cohort Study ◽  
Real World ◽  
The United States ◽  
Elevated Risk ◽  
Breast Cancer Patients ◽  
Increased Risk ◽  
Serious Infections

Abstract Background There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. Methods We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from February 2015 to September 2017 using the HealthCore Integrated Research Database (HIRD), a longitudinal claims database of commercial health plan members in the United States. The historical comparator cohort comprised patients initiating fulvestrant monotherapy from January 2011 to January 2015. Propensity score matching and Cox regression were used to estimate hazard ratios for various safety events. For acute liver injury (ALI), additional analyses and medical record validation were conducted. Results There were 2445 patients who initiated palbociclib including 566 new users of palbociclib-fulvestrant, and 2316 historical new users of fulvestrant monotherapy. Compared to these historical new users of fulvestrant monotherapy, new users of palbociclib-fulvestrant had a greater than 2-fold elevated risk for neutropenia, leukopenia, thrombocytopenia, stomatitis and mucositis, and ALI. Incidence of anemia and QT prolongation were more weakly associated, and incidences of serious infections and pulmonary embolism were similar between groups after propensity score matching. After adjustment for additional ALI risk factors, the elevated risk of ALI in new users of palbociclib-fulvestrant persisted (e.g. primary ALI algorithm hazard ratio (HR) = 3.0, 95% confidence interval (CI) = 1.1–8.4). Conclusions This real-world study found increased risks of several adverse events identified in clinical trials, including neutropenia, leukopenia, and thrombocytopenia, but no increased risk of serious infections or pulmonary embolism when comparing new users of palbociclib-fulvestrant to fulvestrant monotherapy. We observed an increased risk of ALI, extending clinical trial findings of significant imbalances in grade 3/4 elevations of alanine aminotransferase (ALT).

Sign in / Sign up

Export Citation Format

Share Document